Cargando…

Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study

AIM: To determine in vitro susceptibility of multiresistant bacterial isolates to fosfomycin. METHODS: In this prospective in vitro study (local non-random sample, level of evidence 3), 288 consecutively collected multiresistant bacterial isolates from seven medical centers in Croatia were tested fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielen, Luka, Likić, Robert, Erdeljić, Viktorija, Mareković, Ivana, Firis, Nataša, Grgić-Medić, Marijana, Godan, Ana, Tomić, Ivan, Hunjak, Blaženka, Markotić, Alemka, Bejuk, Danijela, Tičić, Vladimira, Balzar, Silvana, Bedenić, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941293/
https://www.ncbi.nlm.nih.gov/pubmed/29740989
http://dx.doi.org/10.3325/cmj.2018.59.56
_version_ 1783321260305940480
author Bielen, Luka
Likić, Robert
Erdeljić, Viktorija
Mareković, Ivana
Firis, Nataša
Grgić-Medić, Marijana
Godan, Ana
Tomić, Ivan
Hunjak, Blaženka
Markotić, Alemka
Bejuk, Danijela
Tičić, Vladimira
Balzar, Silvana
Bedenić, Branka
author_facet Bielen, Luka
Likić, Robert
Erdeljić, Viktorija
Mareković, Ivana
Firis, Nataša
Grgić-Medić, Marijana
Godan, Ana
Tomić, Ivan
Hunjak, Blaženka
Markotić, Alemka
Bejuk, Danijela
Tičić, Vladimira
Balzar, Silvana
Bedenić, Branka
author_sort Bielen, Luka
collection PubMed
description AIM: To determine in vitro susceptibility of multiresistant bacterial isolates to fosfomycin. METHODS: In this prospective in vitro study (local non-random sample, level of evidence 3), 288 consecutively collected multiresistant bacterial isolates from seven medical centers in Croatia were tested from February 2014 until October 2016 for susceptibility to fosfomycin and other antibiotics according to Clinical and Laboratory Standards Institute methodology. Susceptibility to fosfomycin was determined by agar dilution method, while disc diffusion were performed for in vitro testing of other antibiotics. Polymerase chain reaction and sequencing was performed for the majority of extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae (K. pneumoniae) and carbapenem-resistant isolates. RESULTS: The majority of 288 multiresistant bacterial isolates (82.6%) were susceptible to fosfomycin. The 236 multiresistant Gram-negative isolates showed excellent susceptibility to fosfomycin. Susceptibility rates were as follows: Escherichia coli ESBL 97%, K. pneumoniae ESBL 80%, Enterobacter species 85.7%, Citrobacter freundii 100%, Proteus mirabilis 93%, and Pseudomonas aeruginosa 60%. Of the 52 multiresistant Gram-positive isolates, methicillin-resistant Staphylococcus aureus showed excellent susceptibility to fosfomycin (94.4%) and vancomycin-resistant enterococcus showed low susceptibility to fosfomycin (31%). Polymerase chain reaction analysis of 36/50 ESBL-producing K. pneumoniae isolates showed that majority of isolates had CTX-M-15 beta lactamase (27/36) preceded by ISEcp insertion sequence. All carbapenem-resistant Enterobacter and Citrobacter isolates had bla(VIM-1) metallo-beta-lactamase gene. CONCLUSION: With the best in vitro activity among the tested antibiotics, fosfomycin could be an effective treatment option for infections caused by multiresistant Gram-negative and Gram-positive bacterial strains in the hospital setting.
format Online
Article
Text
id pubmed-5941293
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-59412932018-05-11 Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study Bielen, Luka Likić, Robert Erdeljić, Viktorija Mareković, Ivana Firis, Nataša Grgić-Medić, Marijana Godan, Ana Tomić, Ivan Hunjak, Blaženka Markotić, Alemka Bejuk, Danijela Tičić, Vladimira Balzar, Silvana Bedenić, Branka Croat Med J Basic Science AIM: To determine in vitro susceptibility of multiresistant bacterial isolates to fosfomycin. METHODS: In this prospective in vitro study (local non-random sample, level of evidence 3), 288 consecutively collected multiresistant bacterial isolates from seven medical centers in Croatia were tested from February 2014 until October 2016 for susceptibility to fosfomycin and other antibiotics according to Clinical and Laboratory Standards Institute methodology. Susceptibility to fosfomycin was determined by agar dilution method, while disc diffusion were performed for in vitro testing of other antibiotics. Polymerase chain reaction and sequencing was performed for the majority of extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae (K. pneumoniae) and carbapenem-resistant isolates. RESULTS: The majority of 288 multiresistant bacterial isolates (82.6%) were susceptible to fosfomycin. The 236 multiresistant Gram-negative isolates showed excellent susceptibility to fosfomycin. Susceptibility rates were as follows: Escherichia coli ESBL 97%, K. pneumoniae ESBL 80%, Enterobacter species 85.7%, Citrobacter freundii 100%, Proteus mirabilis 93%, and Pseudomonas aeruginosa 60%. Of the 52 multiresistant Gram-positive isolates, methicillin-resistant Staphylococcus aureus showed excellent susceptibility to fosfomycin (94.4%) and vancomycin-resistant enterococcus showed low susceptibility to fosfomycin (31%). Polymerase chain reaction analysis of 36/50 ESBL-producing K. pneumoniae isolates showed that majority of isolates had CTX-M-15 beta lactamase (27/36) preceded by ISEcp insertion sequence. All carbapenem-resistant Enterobacter and Citrobacter isolates had bla(VIM-1) metallo-beta-lactamase gene. CONCLUSION: With the best in vitro activity among the tested antibiotics, fosfomycin could be an effective treatment option for infections caused by multiresistant Gram-negative and Gram-positive bacterial strains in the hospital setting. Croatian Medical Schools 2018-04 /pmc/articles/PMC5941293/ /pubmed/29740989 http://dx.doi.org/10.3325/cmj.2018.59.56 Text en Copyright © 2018 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic Science
Bielen, Luka
Likić, Robert
Erdeljić, Viktorija
Mareković, Ivana
Firis, Nataša
Grgić-Medić, Marijana
Godan, Ana
Tomić, Ivan
Hunjak, Blaženka
Markotić, Alemka
Bejuk, Danijela
Tičić, Vladimira
Balzar, Silvana
Bedenić, Branka
Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title_full Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title_fullStr Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title_full_unstemmed Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title_short Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
title_sort activity of fosfomycin against nosocomial multiresistant bacterial pathogens from croatia: a multicentric study
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941293/
https://www.ncbi.nlm.nih.gov/pubmed/29740989
http://dx.doi.org/10.3325/cmj.2018.59.56
work_keys_str_mv AT bielenluka activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT likicrobert activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT erdeljicviktorija activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT marekovicivana activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT firisnatasa activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT grgicmedicmarijana activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT godanana activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT tomicivan activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT hunjakblazenka activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT markoticalemka activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT bejukdanijela activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT ticicvladimira activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT balzarsilvana activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy
AT bedenicbranka activityoffosfomycinagainstnosocomialmultiresistantbacterialpathogensfromcroatiaamulticentricstudy